

## Daftar Pustaka

1. Adriene K. Breast Cancer: Increasing Incidence, Limited Option. *The Outlook*. June 2002;19 : 1-14
2. Jemal A, Siegel R, Ward E,. *Cancer Statistic 2008*. *CA Cancer J Clin*. 2008;58:71-96.
3. Seouw A., Duffy, S.W., Mc. Gee, M.A., Lee, J., Lee, H.P. Breast Cancer in Singapore. Trends in Incidence 1968-1992, *Int. J. Of Epid.*, 1996; 25 (1), 40-5.
4. Tjindarbumi D, Tjahjadi G, Ramli M. Longitudinal Clinicopathological Follow Up of Breast Cancer Patients from 1988 to 1996 in Jakarta. *MJI*. 1998 ; 109-16.
5. Sugito H. Kanker Di Indonesia Tahun 1994 Data Histopatologik. Badan Registrasi Kanker, Ikatan Ahli Patologi Indonesia : Dirjen Yan.Med.Depkes RI.1994:2-6.
6. Sarjadi, Trihartini. Cancer Registration in Indonesia. *Asian Pasific J.Cancer Prev. IACR Supplement*,2001;2:21-4.
7. Lehnert M. Chemotherapy resistance in breast cancer, *Anticancer Res. De partment C of Internal Medicine, Kantons hospital St. Gallen, Switzerland*. 1998 May-Jun;18(3C):2225
8. Badan Penelitian dan Pengembangan Kesehatan. Survei Kesehatan Rumah Tangga (SKRT). Jakarta : Dep.Kes.RI dan Biro Pusat Statistik.. 1992:44
9. Spiridon E, Kintzios, Barberaki MG. *Plants That Fight Cancer*. California. CRC Press LLC. 2004: 125-7
10. Amin A, Muhtasib HG, Ocker M, Stock RS. Overview of Major Classes of Plant-Derived Anticancer Drugs. *Int J Biomed Sci*. 2009; 5(1):1-11
11. Gilani AA. A Review of Medical Uses and Pharmacological Activities of *Nigella Sativa*. *Pakistan J Bioll Sci*. ©Asian Network for Scientific Information. 2004. 7 (4):441-51
12. El-Din K. The Black Seed *Nigella sativa* Linnaeus - A Mine for Multi Cures: A Plea for Urgent Clinical Evaluation of its Volatile Oil. *J T U Med. Sc*. 2006; 1 (1): 1-19.
13. Field CJ. Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function : lessons from n-3 fatty acids. *Am J of Clin Nut*, June 2004; 79 : 1190-8.
14. Farah IO, Begum RA. Effect of *Nigella sativa* (*N. sativa* L.) and oxidative stress on the survival pattern of MCF-7 breast cancer cells. *Biomed Sci Instrum*. 2003;39(1):359-64.
15. Zaoui A, Cherrah Y, Mahassini N, Alaoui K, Amarouch H, Hassar M. Acute and chronic toxicity of *Nigella sativa* fixed oil. *Phytomedicine*. 2002 Jan;9(1):69-74.
16. Ivankovic S, R. Stojkovic, M. Jukic,M. Milos,M. Milos, M. Jurin. The antitumor activity of thymoquinone and thymohydroquinone in vitro and in vivo. *Exp Oncol* 2006. 28(3) : 220–24.

17. Salim El, Fukushima S. Chemopreventive Potential of Volatile Oil From Black Cumin (*Nigella sativa* L.) Seeds Against Rat Colon Carcinogenesis. *Nutr Cancer*. 2003;45(2):195-202.
18. Badary OA, Gamal El-Din AM. Inhibitory effects of thymoquinone against 20-methylcholanthrene-induced fibrosarcoma tumorigenesis. *Cancer Detect Prev*. 2001;25(4):362-8.
19. Worthen DR, Ghosheh OA, Crooks PA. The in vitro anti-tumor activity of some crude and purified components of blackseed, *Nigella sativa* L. *Anticancer Res* May-Jun.1998;18(3A):1527-32.
20. Khan N, Sharma S, Sultana S. *Nigella sativa* (black cumin) ameliorates potassium bromate-induced early events of carcinogenesis: diminution of oxidative stress. *Hum Exp Toxicol*. Apr 2003;22(4):193-203.
21. Wafaa A, Ahmed, Sohair A. Hassan, Fayek M.Galeb, Maha A, et all. The In vitro Promising Therapeutic Activity of Thymoquinone on Hepatocellular Carcinoma (HepG2) Cell Line. *Global Veterinaria* 2008; 2 (5): 233-41.
22. Ahmed M. Shoieb, Mona Elgayar, Paul S. Dudrik, John L, et al. In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. *Int J Onc*.2003; 22: 107-13.
23. Clemons M and Goss P,. Estrogen and the risk of breast cancer. *N Engl J Med* 2001; 344:276 – 85.
24. Amin FM, Reem H and Ronald IC. *Nigella Sativa* modulates splenocyte proliferation, Th1/Th2 cytokine profile, macrophage function and NK anti tumor activity. *J Ethnopharm*. Sept 2010: 13 (2) : 268-75.
25. El-Obeid A, Al-Harbi S, Al-Jomah N and Hassib A. Herbal melanin modulates TNF-alpha, IL-6 and VEGF production. *J Phytother and Phytopharm*. May 2006 : 13 (5); 324-33.
26. Navdeep , Galina C, Qiaoke G, Charles JY and Hwya A Arafat. Anti-inflammatory effects of *Nigella sativa* seed extract, thymoquinone, in pancreatic cancer cells. *Departement Of Surgery, Thomas Jefferson University, Philadelphia, USA*. August 2009; 11(5): 373-81<sup>26</sup>
27. Jardines L, Haffty BG, Doroshov JH, Fisher P, Weitzel. Breast cancer. Dalam:Pazdur R, Cola LR, Hoskins WJ, Wagman LD (eds). *Cancer Management, A Multidiciplinary Approach*.. New York. The Oncology Group. 2003:163 -235.
28. Asco. *Cancer Genetics & Cancer Predisposition Testing*. 2nd Edition. Alexandria American Society of Clinical Oncology.. 2004; 651-66.
29. Dickson RB, Lippman ME. *Molecular Biology of Breast Cancer*. Dalam:De Vita Jr VT, Hellman S, Rosenberg SA (eds). *Cancer, Principles&Practice of Oncology*, 7th edition. Philadelphia:Lippincott Williams & Wilkins. 2005;1633- 51.
30. DeVita, Vincent T., Hellman, Samuel; Rosenberg, Steven A. *Pharmacology of Endocrine Manipulation*. *Cancer: Principles & Practice of Oncology*, 7th Edition Philadelphia: Lippincott Williams & Wilkins. 2005;17: 456-67
31. DeVita, Vincent T., Hellman, Samuel; Rosenberg, Steven A. *Etiology of Cancer*. *Cancer: Principles & Practice of Oncology*, 7th Edition. Philadelphia : Lippincott Williams & Wilkins. 2005; 7: 165-85.

32. Willett WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz. Epidemiology and nongenetic causes of breast cancer. Dalam :Harris JR, Lippmann ME, Morrow M, Osborne CK(eds): Diseases of the Breast . Second edition. Philadelphia : Lippincott, Williams&Wilkins, 2000; 175-220.
33. William C. Wood, Hyman B. Muss, Lawrence J. Solin, Olufunmilayo I. Olopade - Cancer of the Breast. Dalam: DeVita.; Cancer: Principles & Practice of Oncology, 7th Edition. Philadelphia : Lippincott Williams & Wilkins. 2005; 33:1400-85.
34. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. 5<sup>th</sup> Ed. WB. Saunders Company: Philadelphia, 2007;94-7;177-9.
35. Constantinides P. General Pathobiology. Connecticut : Appleton & Lange. 1994; 34-9.
36. Contran RS, Kumar V, Robbins SL. Robin Pathologic basis of disease. 5<sup>th</sup> ed. Philadelphia : WB Saunders.1994 : 534.
37. Sarjadi. Karsinoma epidermoid serviks uteri (Beberapa aspek epidemiologi serta peran histopatologi dan petanda tumor dalam penentuan prognosis). Disertasi doctor. Semarang : Universitas Diponegoro., 1985;112-4.
38. Hengartner, MO. Programmed cell death in the nematode *C. elegans*. Recent Prog Horm Res. 1999; **54**: 213-22.
39. Csipo, I., Montel, A. H., Hobbs, J. A., Morse, P. A., Brahmi, Z. Effect of Fas+ and Fas- target cells on the ability of NK cells to repeatedly fragment DNA and trigger lysis via the Fas lytic pathway.1998; 105-14.
40. Scaffidi, C, Fulda, S, Srinivasan, A, Friesen, C, Li, F, Tomaselli, KJ, Debatin, KM, Krammer, PH and Peter, ME. Two CD95 (APO-1/Fas) signaling pathways. *Embo J* 1998; 17(6): 1675-87
41. Luo X, Budihardjo, I Zou, H, Slaughter C and Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.1998; 94(4): 481-90.
42. Adrain C., Creagh, E. M., and Martin, S. J. Caspase Cascades in Apoptosis. Caspases-their role in cell death and cell survival. Ed. Marek Los and Henning Walczak. *Moleculare Biology Intelligence Unit 24*. New York. 2002; 41-51.
43. Osama AB. Acute and subchronic toxicity of thymoquinone in mice. *Drug Development Research*. Wiley-Liss, Inc., A Wiley Company 2009;44(2-3): 56 – 61.
44. Earnshaw WC, Martins LM and Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. *New York. Annu Rev Biochem*.1999: 383-424.
45. Hague A, Paraskeva C. Apoptosis and disease: a matter of cell fate. *Nature Cell Death and Differentiation*. *J Immun*.2004; 1-7.
46. Abou-Basha L, Rashed M, Aboul-Enein H. TLC assay of thymoquinone in black seed oil (*Nigella sativa* Linn.) and identification of dithymoquinone and thymol. *J Lqd Chrom*. 1995. 18(1): 105-15.
47. Khan M. Chemical composition and medicinal properties of *Nigella sativa* Linn. *Inflammopharmacol*. 1997; 1(1): 15-35.

48. El-Tahir KED, Bakeet DM, The Black Seed *Nigella sativa* Linnaeus - A Mine for Multi Cures: A Plea for Urgent Clinical Evaluation of its Volatile Oil. *J T U Med Sc.* 2006; 1 (1): 1-19.
49. Padhye S, Banerjee S, Ahmad A, Mohammad R, Fazlul HS. From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. *Cancer Ther.* 2008 ; 6(b): 495–510.
50. Salem ML. Immunomodulatory and therapeutic properties of the *Nigella sativa* L. seed. *Int Immunopharmacol.* 2005 Dec;5(13-14):1749-70. Epub 2005 Jul 1.
51. Ghosheh O, Houdi A, Crooks P. High Performance Liquid Chromatographic Analysis of the Pharmacologically Active Quinones and Related Compounds in the Oil of the Black Seed (*Nigella sativa* L.). *J. Biomed and Pharmaceutl Anal.* 1999; 19: 757-62.
52. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Ying W, et al. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. *Mol Cancer Ther* July 2008;7(7):201-22.
53. Ahmed MS, Mona E, Paul SD, John LB, Atricia KT. *In vitro* inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. *Int J of Onc.* 2003; 22: 107-13.
54. Hassana SA., Wafaa AA., Fayek MG., El-Taweeld MA., Farid AA. *In Vitro* Challenge using Thymoquinone on Hepatocellular Carcinoma (HepG2) Cell Line. *Iranian J Pharmaceut Res* 2008; 7 (4): 283-90
55. Amin A, Muhtasib H., Ocker M Stock RS, Overview of Major Classes of Plant-Derived Anticancer Drugs. *Int J Biomed Sci* 2009; 5(1):1-11
56. Nazrul ISK, Begum F, Ahsan T, Hague S. Immunosuppressive and cytotoxic properties of *Nigella sativa*. *Phytothera Res* 2004; 18, 395-8.
57. Salomi N, Nair S, Jayawardhanan K, Vorghese C, and Panikkar K. Antitumor principles from *Nigella sativa* seeds. *Cancer Letters* 1992.63(1): 41-6.
58. Champe PC. *Biochemistry.* Baltimore. Lippincott William Wilkins,. 2005; 171-8.
59. Mostofsky DI. *Fatty acids: physiological and behavioral functions.* New Jersey: Humana Press inc,. 2001; 404-6.